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Psycho‐Oncology. 2019;1–9.Abstract
Objective: Even when medical treatments are limited, supporting patients’ coping
strategies could improve their quality of life. Greater understanding of patients’ cop-
ing strategies, and influencing factors, can aid developing such support. We examined
the prevalence of coping strategies and associated variables.
Methods: We used sociodemographic and baseline data from the ACTION trial,
including measures of Denial, Acceptance, and Problem‐focused coping (COPE; Brief
COPE inventory), of patients with advanced cancer from six European countries. Cli-
nicians provided clinical information. Linear mixed models with clustering at hospital
level were used.
Results: Data from 675 patients with stage III/IV lung (342, 51%) or stage IV colorec-
tal (333, 49%) cancer were used; mean age 66 (10 SD) years. Overall, patients scored
low on Denial and high on Acceptance and Problem‐focused coping. Older age was
associated with higher scores on Denial than younger age (β = 0.05; CI[0.023;
0.074]), and patients from Italy (β = 1.57 CI[0.760; 2.388]) and Denmark (β = 1.82 CI
[0.881; 2.750]) scored higher on Denial than patients in other countries.
Conclusions: Patients with advanced cancer predominantly used Acceptance and
Problem‐focused coping, and Denial to a lesser extent. Since the studied coping strat-
egies of patients with advanced cancer vary between subpopulations, we recommend
taking these factors into account when developing tailored interventions to support
patients’ coping strategies.
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Patients diagnosed with advanced, incurable cancer commonly experi-
ence physical and psychological symptom burden.1,2 When the dis-
ease has progressed to a point where curative treatments are
unavailable, patients can particularly benefit from interventions aimed
at improving quality of life.2
One way of assisting patients in the last phase of their lives is by
supporting adaptive coping strategies. Coping strategies are distinct,
ever changing cognitive, emotional and behavioral efforts to manage
a (health) threat.3 For instance, when using denial, patients reduce
the impact of their advanced disease by thinking that it is not real.4
Acceptance includes actively dealing with the advanced disease with-
out unnecessary attempts to change the circumstances.5 Problem‐
focused coping extends this towards a behavioral approach, for exam-
ple, through taking actions to improve their way of living with their
advanced disease.4 The use of coping strategies can vary between
patients, situations, and over time.4 Different coping strategies may
be used simultaneously or alternately.6 Whether a certain coping
strategy is adaptive or not depends on the individual patient and situ-
ational context.4,7,8
Evidently, the way patients cope with their advanced disease
impacts physical and psychological outcomes, such as quality of life
and depressive symptoms.2 Since coping strategies are modifiable,4
supporting and encouraging adaptive coping strategies can contribute
to the well‐being of patients, also when their disease has reached an
advanced, incurable stage.9 Therefore, coping support is incorporated
into interventions for patients with advanced cancer.10,11 Coping
strategies can also be used to tailor interventions. For instance, a trial
compared a generic pain management program for older adults to pro-
grams matched to patients’ initial tendency towards either problem‐
focused or emotion‐focused coping. Patients with problem‐focused
coping were provided with specific instructions for relaxation and
problem‐solving activities, patients with emotion‐focused coping
received specific information on seeking support and expressing hope.
The tailored interventions were more successful in reducing pain and
symptoms of anxiety.12
The relevance of assessing and responding to coping needs
throughout the disease trajectory of patients has been confirmed
and recognized by numerous professional organizations, such as the
American Society of Clinical Oncology13 and the National Institute
for Clinical Excellence in the United Kingdom.14 Research in this area
has mainly focused on patients in earlier stages of cancer.15-17 It is
unclear if the findings in these patients are generalizable to patients
with advanced cancer who face specific challenges, such as prepara-
tory grief18 and increased existential distress.19
Given the importance of the sociocultural context for the appraisal
of a (health) threat, it is not surprising that coping strategies have beenfound to differ among people with different socio‐cultural characteris-
tics. For instance, younger people tend to use more active, problem‐
focused coping than older people,20 and Korean Americans and Fili-
pino Americans seemed to use more religious coping and escape
avoidance than Caucasian Americans.21,22 It is however unknown to
what extent sociodemographic and clinical variables relate to the cop-
ing strategies of patients with advanced cancer. Detailed insights into
coping strategies of patients with advanced cancer can inform both,
the design of interventions delivering coping support and the evalua-
tion and improvement of existing interventions by tailoring them to
patients’ individual coping strategies.
We aimed to (1) characterize the prevalence of denial, acceptance,
and problem‐focused coping among patients with advanced lung or
colorectal cancer and (2) identify sociodemographic and clinical char-
acteristics associated with the use of these coping strategies, including
a comparison between countries.2 | METHODS
We used the sociodemographic and baseline data of patients of the
ACTION trial, a cluster randomized trial investigating the effects of
an advance care planning intervention compared to care as usual.
We included only patients from the care‐as‐usual arm of this cluster‐
randomized trial to avoid potential selection bias. Patients were
recruited in outpatient pulmonology and oncology departments in aca-
demic and nonacademic hospitals in Belgium, Denmark, Italy, the
Netherlands, Slovenia, and the United Kingdom, between June 2015
and May 2017 (see Box 1 for the inclusion and exclusion criteria).23
Written informed consent was obtained. Research ethics committees
of the participating countries approved the trial.Box 1. Inclusion and Exclusion Criteria for the
ACTION trial.
Inclusion criteria
1. Histologically confirmed diagnosis of:
a. Lung cancer:
• Small cell – extensive disease/ Stage III or IV*
• Non‐small cell – stage III or IV*
• Colorectal cancer: Stage IV or metachronous metastases*,
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*according to the 7th edition of TNM classification and staging
system
• Written informed consent to participate,
• WHO performance status of 0‐3
Exclusion criteria:
1. Age <18 years,
2. Unable to provide consent,
3. Unable to complete questionnaire in country's language,
4. Less than 3 months anticipated life expectancy,
5. Taking part in a research study that is evaluating palliative
care services or communication strategies.2.1 | Measures
2.1.1 | Sociodemographic and clinical variables
Patients provided information about their age, educational level, gen-
der, living situation, and religion. Their healthcare providers registered
type and stage of the disease and the time since diagnosis of the pri-
mary tumor and current stage of the disease, and on current treat-
ment and performance status according to the World Health
Organization (WHO) scale (0‐fully active to 3‐capable of only limited
self‐care).242.1.2 | Coping
We measured patients’ coping strategies with the subscales Denial
and Acceptance of the COPE Inventory and the subscales Planning
and Active coping of the Brief COPE.7,25 Patients were asked to rate
the items according to the best description of how they had been cop-
ing with their disease during the past two months. Items were rated on
a four‐point Likert scale from 1 (“I don't do this at all”), 2 (“I do this a
little bit”), 3 (“I do this a medium amount”), to 4 (“I do this a lot”).
Following questionnaire instructions, we confirmed the subscales
of the underlying coping strategies,7 by conducting a principal compo-
nents analysis with the 12 selected items of the questionnaires. The
analysis identified three distinct factors, each with eigenvalues above
1. The analysis confirmed the two subscales Denial and Acceptance.7
The subscales Active coping and Planning of the Brief COPE loaded
on the same factor, in accordance with the structure of the question-
naire as described by the developers.25 We therefore combined Active
coping and Planning, and, following previous research,26 labeled the
resulting subscale “Problem‐focused coping” (see Box 2 for an over-
view of the subscales and included questions). For detailedpsychometric information see Table S1. We summed the responses
per subscale to create subscale sum scores. This resulted in a range
of 4 to 16 for each subscale. Higher scores indicate more use of that
particular coping strategy.Box 2. Overview of the Subscales and items of the
COPE and the brief COPE after the Principal
Component Analysis.
Denial
1. I act as though this hasn't even happened.
2. I say to myself “this isn't real”
3. I pretend that this hasn't really happened to me.
4. I refuse to believe that this happened to me.
Acceptance:
1. I accept the reality of the fact that this has happened to me.
2. I learn to live with my situation.
3. I get used to the idea that this has happened to me.
4. I accept that this has happened to me and that it can't be
changed.
Problem‐focused coping
1. I concentrate my efforts on doing something about my
situation.
2. I take action to try to make my situation better.
3. I try to come up with a strategy about what to do in my
situation.
4. I think hard about what steps to take in my situation.2.2 | Statistical methods
Missing items are common in palliative care trials.27 Given the low per-
centage of missing items (<5%) in our study, we carried out a complete
case analysis by including only data of patients with full responses on
all items of the three respective coping subscales.
We used SPSS 24 for the analyses. We summarized patients’
sociodemographic and clinical characteristics with means and standard
deviations for continuous variables and counts and percentages for
categorical variables. The distribution of scores on the coping sub-
scales is presented with mean sum scores and standard deviations.
Pearson correlation coefficients describe the linear correlation
between coping strategies.
Multivariate multilevel regression models were used to analyze
associations between coping strategies and sociodemographic and
TABLE 1 Sociodemographic and clinical characteristics
Belgium
(n = 135)
Denmark
(n = 68)
Italy
(n = 139)
Netherlands
(n = 168)
Slovenia
(n = 25)
United Kingdom
(n = 140)
Total
(N = 675)
Age (years), mean (SD) 65.3 (9.5) 65.5 (9.0) 65.5 (9.6) 65.4 (8.1) 71.1 (9.5) 68.4 (11.0) 66.2 (9.6)
Years of education, mean (SD) 13.9 (4.4) 13.5 (5.9) 11.4 (5.2) 13.2 (3.7) 9.9 (3.3) 13.5 (4.7) 12.9 (4.7)
Gender (male), n (%) 91 (67.4) 35 (51.5) 90 (64.7) 111 (66.1) 10 (40.0) 70 (50.4) 407 (60.4)
Living with a spouse, n (%) 106 (79.1) 55 (80.9) 99 (73.9) 129 (78.2) 15 (62.5) 93 (69.9) 497 (75.5)
Having children, n (%) 114 (85.1) 62 (91.2) 118 (86.8) 146 (86.9) 21 (84.0) 60 (44.1) 583 (87.3)
Religion, n (%)
Not specified 31 (23.8) 9 (13.6) 16 (11.7) 17 (10.1) 2 (8.0) 18 (13.2) 93 (14.0)
Not religious 30 (23.1) 38 (57.6) 24 (17.5) 76 (45.2) 2 (8.0) 58 (42.6) 228 (34.4)
Religious 69 (53.1) 19 (28.8) 97 (70.8) 75 (44.6) 21 (84.0) 60 (44.1) 341 (51.5)
Diagnosis, n (%)
Lung cancer stage III/IV 79 (58.5) 34 (50.0) 71 (51.1) 76 (45.2) 0 (0.0) 82 (58.6) 342 (50.7)
Colorectal cancer stage IV 56 (41.5) 34 (50.0) 68 (48.9) 92 (54.8) 25 (100) 58 (41.4) 333 (49.3)
Years since diagnosis,
mean (SD)
1.5 (1.7) 2.7 (3.2) 2.0 (3.5) 1.9 (1.9) 2.3 (2.4) 0.9 (1.4) 1.7 (2.4)
Years since diagnosis
current stage, mean (SD)
1.1 (1.4) 1.6 (2.2) 0.8 (1.1) 1.2 (1.4) 1.3 (1.9) 0.4 (0.7) 1.0 (1.4)
Current systemic treatment,†
n (%)
126 (96.2) 68 (100.0) 135 (97.1) 144 (86.2) 8 (53.3) 115 (87.8) 596 (91.6)
WHO performance status, n (%)
3 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.2) 1 (4.0) 5 (3.6) 8 (1.2)
2 7 (5.5) 1 (1.5) 2 (1.4) 12 (7.1) 13 (52.0) 20 (14.3) 55 (8.3)
1 56 (44.1) 40 (58.8) 65 (47.1) 122 (72.6) 10 (40.0) 49 (35.0) 342 (51.4)
0 64 (50.4) 27 (39.7) 71 (51.4) 32 (19.0) 1 (4.0) 66 (47.1) 261 (39.2)
SD = standard deviation
†Includes chemotherapy, immunotherapy, targeted therapy; treatments were not mutually exclusive.
Missings total: Age (n = 6), Education (n = 89), Gender (n = 1), Living with a spouse (n = 15), Having children (n = 6), Religion (n = 13), Years since diagnosis (n
= 1), Years since diagnosis current stage (n = 6), Systemic treatment (n = 24), WHO performance status (n = 9).
4 JABBARIAN ET AL.clinical variables. This type of model allows accounting for clustering at
the hospital level and thus for nonindependency of observations.28
For inclusion numbers per hospital, seeTable S2. The variable Country
was included as a confounder. First, bivariate multilevel models were
used to test associations between each sociodemographic and clinical
variable and the distinct coping strategies. A significance level of p <
0.20 was used to select variables for the final model.29 For the final
multivariate model, the significance level was set at p < 0.05. The
Benjamini‐Hochberg procedure was used to account for the false dis-
covery rate.30 Betas, 95% confidence intervals and Benjamini‐
Hochberg p‐values are reported.3 | RESULTS
The analyses included 675 patients enrolled in the control arm of the
ACTION trial. Numbers of patients per country ranged from n = 25
(Slovenia) to n = 168 (the Netherlands, Table 1). Patients’ average
age was 66 (SD 9.6) years, the majority of patients were male (60%).Most of the patients were living with a partner (76%) and had children
(87%), half of them described themselves as being religious (52%). Half
of the population was diagnosed with lung cancer stage III or IV (51%).
On average, patients were diagnosed with their primary tumor 1.7
years prior to inclusion (2.4 SD). Most patients received systemic anti-
tumor treatment (92%) at time of inclusion.3.1 | Prevalence of coping strategies
Patients scored low on Denial (mean sum score 6.6 (SD 3.1) and
high on Acceptance and Problem‐focused coping (mean sum score
12.6 [SD 2.7] and 12.2 [SD 2.9], respectively; Table 2). Higher scores
on Acceptance were correlated with higher scores on Problem‐
focused coping (r = 0.36; p < 0.001), higher scores on Problem‐
focused coping were correlated with higher scores on Denial (r =
0.11; p < 0.001). Denial and Acceptance were not correlated (r =
0.04; p = 0.267).
TABLE 2 Patient mean sum scores (SD) on coping subscales by
sociodemographic and clinical characteristics
Denial†
(n = 655)
Acceptance†
(n = 659)
Problem‐
focused†
(n = 643)
Mean Sum Score (SD) 6.6 (3.1) 12.6 (2.7) 12.2 (2.9)
Age in years
18‐64 6.1 (2.8) 12.6 (2.9) 12.6 (2.7)
65‐79 6.9 (3.2) 12.6 (2.5) 12.0 (2.8)
≥80 7.3 (3.9) 13.3 (3.0) 11.5 (3.6)
Years of education
0‐4 6.4 (2.8) 12.5 (2.2) 10.4 (3.3)
5‐12 7.0 (3.3) 12.3 (2.8) 12.2 (2.8)
≥13 6.1 (2.8) 12.9 (2.5) 12.3 (2.9)
Gender
Male 6.6 (3.1) 12.5 (2.7) 12.0 (3.0)
Female 6.6 (3.2) 12.8 (2.8) 12.6 (2.7)
Living with a spouse
Yes 6.6 (3.0) 12.6 (2,7) 12.2 (2.8)
No 6.7 (3.5) 12.6 (2.6) 12.1 (3.1)
Having children
Yes 6.7 (3.2) 12.6 (2.7) 12.2 (2.9)
No 5.8 (2.5) 12.8 (2.7) 12.4 (2.9)
Religion
Not specified 6.5 (3.0) 12.0 (2.9) 11.7 (3.0)
Not religious 6.3 (3.1) 12.7 (2.7) 12.2 (2.9)
Religious 6.9 (3.1) 12.7 (2.6) 12.5 (2.8)
Diagnosis
Lung cancer stage III/IV 6.7 (3.1) 12.4 (2.6) 12.1 (2.8)
Colorectal cancer stage IV 6.6 (3.1) 12.8 (2.8) 12.3 (3.0)
Years since diagnosis
≤1 year 6.5 (3.0) 12.7 (2.7) 12.3 (2.8)
> 1 year 6.5 (3.1) 12.8 (2.8) 12.4 (3.1)
Years since diagnosis
current stage
≤0.5 year 6.5 (3.0) 12.6 (2.6) 12.4 (2.6)
>0.5 year 6.7 (3.3) 12.7 (2.7) 12.0 (3.1)
Current systemic treatment‡ 6.6 (3.1) 12.6 (2.6) 12.2 (2.8)
WHO performance status
3 5.8 (2.4) 13.4 (2.1) 11.3 (1.9)
2 7.2 (3.6) 12.5 (2.8) 11.8 (2.9)
1 6.6 (3.1) 12.3 (2.7) 12.2 (2.8)
0 6.6 (3.0) 12.9 (2.7) 12.4 (3.1)
Country of residence
Belgium 6.5 (2.9) 11.7 (2.8) 10.4 (3.0)
Denmark 7.6 (3.5) 13.3 (2.4) 12.6 (2.9)
Italy 7.5 (3.1) 12.5 (2.5) 12.8 (2.3)
(Continues)
TABLE 2 (Continued)
Denial†
(n = 655)
Acceptance†
(n = 659)
Problem‐
focused†
(n = 643)
Netherlands 6.0 (2.9) 12.5 (2.6) 13.0 (2.4)
Slovenia 7.3 (3.5) 12.6 (2.5) 12.4 (2.6)
United Kingdom 6.1 (3.0) 13.4 (2.8) 12.2 (3.2)
†Range for coping strategies is 4‐16 (higher scores indicate greater use of
coping strategy).
‡Includes chemotherapy, immunotherapy, targeted therapy; treatments
were not mutually exclusive.
Missings range: Age (5‐6), Education (n = 79‐89), Gender (n = 1), Living
with a spouse (n = 14‐15), Children (n = 6), Religion (n = 12‐13), Time since
diagnosis (n = 1), Time since diagnosis current stage (n = 6), Systemic treat-
ment (n = 20‐23), WHO performance status (n = 8‐9).
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3.2.1 | Denial and sociodemographic and clinical
variables
For Denial (n = 655), bivariate multilevel models showed significant
associations (p < 0.20) with age, years of education, having children,
years since the diagnosis of the primary tumor, and country of resi-
dence (Table S3). These variables were included in the final multivari-
ate model (Table 3), which showed that older age was associated with
higher scores on Denial than younger age (β = 0.05; 95% CI
[0.023;0.074], p = 0.010), and patients in Italy (β = 1.57; 95% CI
[0.760; 2.388]; p = 0.010) and Denmark (β = 1.82; 95% CI[0.881;
2.750]; p = 0.010) scored higher than patients in other countries.
3.2.2 | Acceptance and sociodemographic and clini-
cal variables
Bivariate multilevel models for Acceptance (n = 659) showed signifi-
cant associations (p < 0.20) with years of education, being religious
or not, primary diagnosis, years since diagnosis of the primary tumor
and diagnosis of the current stage, WHO performance status, and
country of residence (Table S3). These variables were included in the
final multivariate model (Table 3), which showed no significant
associations.
3.2.3 | Problem‐focused coping and
sociodemographic and clinical variables
For Problem‐focused coping (n = 643), bivariate multilevel models
showed significant associations (p < 0.20) with age, years of education,
gender, being religious or not, years since diagnosis of the primary
tumor, WHO performance status, and country of residence (Table S3
). These variables were included in the final multivariate model
(Table 3). The association between the WHO status and Problem‐
focused coping was borderline significant (p = 0.057) with patients
with a WHO status of 1 (β=−0.75; 95% CI[−1.268; −0.228]) or 2 (β=
TABLE 3 Multivariate multilevel analyses of coping strategies
Denial
(n = 655)
Acceptance
(n = 659)
Problem‐focused
(n = 643)
β 95% CI p β 95% CI p β 95% CI p
Explanatory Variables
Age .049 .023, .074 .010* −.016 −.041, .010 .0.324
Years of education −.042 −.095, .012 .233 .053 .005, .100 .143 .038 −.012, .088 ..233
Gender NA NA .296
Male −.324 −.808, .158
Female Ref
Having children .204 NA NA
Yes .673 −.065, 1.410
No Ref
Religion NA .351 .351
Not specified −.550 −1.230, .127 −.387 −1.100, .326
Not religious −.083 −.585, .418 −.400 −.926, .130
Religious Ref Ref
Diagnosis NA .517 NA
Lung cancer stage III/IV −.181 −.667, .304
Colorectal cancer stage IV Ref
Years since diagnosis .041 −.058, .140 .496 .017 −.090, .124 .772 −.014 −.107, .079 .772
Years since diagnosis current stage NA .156 −.030, .343 .211 NA
WHO performance status NA .204 .057
3 .882 −1.258, 3.022 −1.542 −3.816, .732 .183
2 −.542 −1.523, .438 −1.335 −2.330, −.340 .009*
1 −.591 −1.093, −.088 −.748 −1.268, −.228 .005*
0 Ref Ref
Country of residence .010 .204 .204
Netherlands .081 −.661, .823 .831 −.842 −1.897, .213 1.281 −.558, 3.120
Belgium .689 −.108, 1.486 .090 −1.881 −2.990, −.772 −1.679 −3.677, .319
Slovenia 1.072 −.360, 2.499 .141 −.795 −2.334, .744 .798 −1.657, 3.253
Italy 1.574 .760, 2.388 <.001 −.662 −1.770, .447 .518 −1.480, 2.517
Denmark 1.812 .881, 2.750 <.001 −.186 −1.561, 1.190 .530 −1.936, 3.000
United Kingdom Ref Ref Ref
*p < 0.05
6 JABBARIAN ET AL.−1.33; 95% CI [−2.330; 0.340], ie, somewhat restricted in activities)
scoring lower on Problem‐focused coping than patients with a WHO
status of 0 (ie, fully active).4 | CONCLUSIONS
Patients with advanced lung or colorectal cancer predominantly used
Acceptance and Problem‐focused coping. The coping strategies were
associated with sociodemographic and clinical characteristics.
Our findings that patients scored low on the use of Denial and high
on Acceptance and Problem‐focused coping aligns with observations
in patients with early stage cancer,31 patients recently diagnosed withincurable cancer2 and cancer survivors.32 Our results show that higher
scores on Acceptance were correlated with higher scores on Problem‐
focused coping. Endler and colleagues observed that patients with
acute health problems predominantly used one coping strategy, in an
effort to soothe their symptoms.6 Contrarily, patients with chronic
health problems relied on more than one coping strategy, possibly
because they have to adjust their life styles to a new situation.6 A sim-
ilar challenge might be faced by patients with advanced cancer. Seem-
ingly contradictory coping strategies Denial and Problem‐focused
coping were positively correlated, be it only weakly. Denial includes
pretending that the disease is not real while Problem‐focused coping
concerns taking action to make a situation better.4 Possibly, both
mechanisms are used to distract oneself from the actual situation.
JABBARIAN ET AL. 7Denial itself has been association with negative and positive out-
comes. One study in the United States of America showed that
patients with asthma who scored high on denial tended to disregard
symptoms of breathing difficulty, resulting in a higher rate of hospital-
izations.33 Yet, in a study with patients with lung cancer, high scores
on denial were related to a better overall perception of health and less
pain.8
We found that older age was associated with higher scores on
Denial than younger age. It has been hypothesized that older patients
use “threat minimization” more, which includes keeping feelings to
oneself and avoiding emotional distress by trying to forget.34 Patients
in Italy and Denmark scored higher on Denial than patients in other
countries. A review about culture and end‐of‐life care suggested a
general reluctance to talk about death, as well as a trend towards
partial/no disclosure of patients’ diagnosis and prognosis in Italy and
Norway (a Scandinavian country with supposedly cultural resemblance
to Denmark).35 This tendency was related to respect for privacy
and/or to a strong death taboo,35 which might facilitate Denial as a
way of pretending that the disease is not real. We also found border-
line significant results that patients with a worse WHO performance
status scored lower on Problem‐focused coping than patients who
were fully active. The behavioral efforts often required for Problem‐
focused coping might become more challenging with declining physi-
cal abilities.4.1 | Clinical implications
As Walshe et al stressed,11 a major conceptual issue in current inter-
ventions is that they largely ignore coping strategies of patients with
advanced cancer, which might worsen their psychological experi-
ence.11 The clinical use of our results are twofold: (1) through tailoring
interventions and framing discussions according to patients’ coping
strategies and (2) through offering adequate coping support where
needed. For instance, patients with a better WHO performance status
might benefit from interventions activating their skills and confidence
to manage their disease, acknowledging their tendency towards
problem‐focused coping. For older patients, we advise to consider
their tendency towards denial and adapt, for instance, information
provision through carefully considering the detail of their
information.36
Addressing coping strategies and providing support, eg, as an ele-
ment of a palliative care intervention for patients with advanced can-
cer, is associated with improved quality of life.9 Our findings might
help to decide which coping strategies to include in such interven-
tions. Interestingly, our study showed that patients tend to use accep-
tance and problem‐focused coping more than denial. Referring to the
approach‐avoidance dimension,37 we observed a higher tendency
towards approach‐oriented coping than avoidance‐oriented coping.
Early palliative care has been found to increase patients’ use of
approach‐oriented coping strategies, leading to higher quality of life
and lower depressive symptoms.9 Generic interventions offering
approach‐oriented coping support might thus not be beneficial formost patients, instead interventions should focus on encouraging
and building on pre‐existing strategies. To identify these pre‐existing
strategies, as well as individual needs of patients, assessing coping
strategies might be a useful approach. The Mental Adjustment to Can-
cer (MAC) scales is specifically developed for and widely used in can-
cer and palliative care settings and has shown good measurement
properties.38,394.2 | Strengths
This paper presents unique data of patients with an advanced stage of
two common cancer types in six European countries. We were able to
collect detailed sociodemographic and clinical information, which
allowed a thorough analysis of coping strategies.4.3 | Study limitations and recommendations
To minimize questionnaire burden, we restricted the assessment to
three coping strategies. Future research should include additional cop-
ing strategies, such as spirituality or seeking social support, which
might give more information about cultural sensitivity and relevance
of coping strategies. In this study, we focused on patients with
advanced lung or colorectal cancer. Replication of these findings in
patients with other oncologic diagnoses and advanced diseases is rec-
ommended. Since we observed patients using a combination of differ-
ent coping strategies, we recommend to investigate which
combinations of coping strategies are beneficial for patients, and
how these combinations might develop over time and between coun-
tries. Given that coping strategies are context‐dependent, it would be
informative to determine which coping strategies were used to deal
with which specific challenge. One should note that some beta
weights as well as the differences between the mean sum scores were
small, and replication of our findings is therefore desirable.4.4 | Conclusion
We investigated the prevalence of coping strategies and associated
sociodemographic and clinical characteristics in patients with
advanced cancer in six European countries. We found that patients
with advanced cancer predominantly use Acceptance and Problem‐
focused coping and use different strategies simultaneously. Denial
was used less often. Being aware of the variance in the use of coping
strategies can help healthcare professionals to fine‐tune their care.
Interventions should be tailored to patients’ coping strategies.ACKNOWLEDGEMENTS
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